drugset / Trial / NCT03150160

Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma

NCT03150160

Phase 4 Completed 1 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to determine the incremental intraocular pressure (IOP) lowering that is achieved when Simbrinza is used adjunctively to Travatan in patients with normal tension glaucoma that may benefit from further IOP lowering.

Timeline

Start
2017-09-21
Primary completion
2017-12-04
Completion
2017-12-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 0.2 % Topical
Subject Brinzolamide Small molecule 1 % Topical
Background Travoprost Other / unclassified 0.004 % Topical

Indications